This prospective, single-arm observational trial examines whether aromatase inhibitor therapy in postmenopausal women with HR-positive breast cancer adversely affects cardiorespiratory fitness, skeletal muscle function, and immunosenescence.
J. Schlefman
Advertisement
Articles by J. Schlefman
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Ziftomenib Plus 7+3 Yields High Response Rates in Newly Diagnosed AML
2
Pirtobrutinib Plus Venetoclax/Rituximab Improves PFS in Pretreated CLL
3
Arlo-Cel Produces Deep Responses in Pretreated R/R Multiple Myeloma
4
Liso-Cel Demonstrates Real-World Efficacy in Relapsed/Refractory MCL
5